Physician profile
John M James
NPI 1811907579
$1,538.19
in general payments reported to CMS, 2019-2025
19 companies · $43.10 in 2025
The $43.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $204 · 2021: $345 · 2022: $238 · 2023: $317 · 2024: $203 · 2025: $43.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.20 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.91 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $179.97 | 2021-2022 | |
| Abbvie INC. | $159.49 | 2021-2024 | |
| Exact Sciences Corporation | $145.00 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $144.59 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $108.55 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $80.71 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $79.99 | 2023 | |
| Pfizer INC. | $73.62 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.07 | 2021-2022 | |
| Novo Nordisk INC | $49.45 | 2020-2023 | Rybelsus |
| Novartis Pharmaceuticals Corporation | $47.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.37 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.40 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $18.13 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2020 | |
| Axsome Therapeutics, INC. | $9.28 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.